Celldex Therapeutics Revenue 2006-2021 | CLDX

Celldex Therapeutics revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Celldex Therapeutics Annual Revenue
(Millions of US $)
2020 $7
2019 $4
2018 $10
2017 $13
2016 $7
2015 $5
2014 $4
2013 $4
2012 $11
2011 $9
2010 $47
2009 $15
2008 $7
2007 $1
2006 $1
2005 $3
Celldex Therapeutics Quarterly Revenue
(Millions of US $)
2021-06-30 $3
2021-03-31 $1
2020-12-31 $4
2020-09-30 $1
2020-06-30 $0
2020-03-31 $3
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $2
2018-09-30 $1
2018-06-30 $3
2018-03-31 $4
2017-12-31 $3
2017-09-30 $4
2017-06-30 $4
2017-03-31 $2
2016-12-31 $2
2016-09-30 $2
2016-06-30 $1
2016-03-31 $1
2015-12-31 $2
2015-09-30 $1
2015-06-30 $2
2015-03-31 $0
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $0
2013-12-31 $1
2013-09-30 $1
2013-06-30 $0
2013-03-31 $2
2012-12-31 $4
2012-09-30 $3
2012-06-30 $2
2012-03-31 $2
2011-12-31 $2
2011-09-30 $2
2011-06-30 $2
2011-03-31 $3
2010-12-31 $38
2010-09-30 $2
2010-06-30 $3
2010-03-31 $4
2009-12-31 $5
2009-09-30 $4
2009-06-30 $3
2009-03-31 $4
2008-12-31 $3
2008-09-30 $2
2008-06-30 $2
2008-03-31 $0
2007-12-31 $0
2007-09-30 $0
2007-06-30 $1
2007-03-31 $0
2006-12-31 $0
2006-09-30 $0
2006-06-30 $1
2006-03-31 $4
2005-12-31 $1
2005-09-30 $1
2005-06-30 $1
2005-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.147B $0.007B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00